Key result
Patients with acute coronary syndrome exhibited distinct gut microbiota, reduced bacterial metabolites, and elevated sCD14 and sCD163 compared with healthy controls.
Why the study?
Are there differences in gut microbiota and metabolomics profiles between patients with chronic stable angina or ACS and healthy controls?
Observational
Are there differences in gut microbiota and metabolomics profiles between patients with chronic stable angina or ACS and healthy controls?
Distinct gut microbiota and metabolomic profiles in patients with ACS and chronic stable angina may provide insights into new disease-related mechanisms and therapeutic targets.
ACS microbial-metabolite differences should not change practice; leaves open causal roles in disease development.
The study found discriminative microorganisms differentiating patients with acute coronary syndrome (ACS) from healthy controls. In addition, reduced levels of certain bacterial metabolites and elevated sCD14 and sCD163 were observed in patients with ACS compared with healthy controls. Furthermore, modified small molecule metabolomic and lipidomic signatures were found in both patient groups. Although it is not known whether these differences in profiles are associated with disease development and/or progression, the findings provide exciting options for potential new disease-related mechanism(s) and associated therapeutic target(s).
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2023) conducted an observational in Chronic stable angina and acute coronary syndrome. Acute coronary syndrome and chronic stable angina vs. Healthy controls was evaluated on Gut microbiota and metabolomics profiles. Patients with acute coronary syndrome exhibited distinct gut microbiota, reduced bacterial metabolites, and elevated sCD14 and sCD163 compared with healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: